Cellectar Reports 33% Overall Response Rate in Phase 2 Interim Data for CLR 131 in...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jul 18, 2018 at 11:12 AM.

  1. #1 cafead, Jul 18, 2018 at 11:12 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,984
    Likes Received:
    3
    via
    • Observed responses to date show overall tumor reduction ranged from 60% to greater than 90%
    • Company is expanding trial cohort up to 30 additional patients
    • CLR 131 has orphan drug designation for the treatment of Ewing Sarcoma

    article source
     
    Quote

Reply to Thread